TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02178124
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01948401
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
Study: NCT01948401
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: additional 0.5 mg/kg orally for 7 days
Study: NCT03806127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02699645
Drug: telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill taken orally once daily for average of 72 months
Study: NCT02699645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill taken orally once daily for average of 72 months
Study: NCT02435433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02583191
Drug: low-molecular heparine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily
Study: NCT00494741
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight \> 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
Study: NCT00916045
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04133116
Drug: LY3471851
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04133116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01630616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, tablets
Study: NCT00486434
Drug: SMC021 Oral Calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8mg SMC021 (Oral Calcitoinin) twice daily
Study: NCT00486434
Drug: SMC021 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally, twice daily
Study: NCT01494090
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 or 20 mg per day during 6 months
Study: NCT01494090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 20 mg per day during 6 months
Study: NCT02771054
Drug: TAF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change of nucleoside backbone
Study: NCT01013818
Drug: HGS1029
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
Study: NCT03155893
Drug: SMV Placebo (Matching 150 mg SMV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
Study: NCT02456350
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
Study: NCT00627120
Drug: VGX-1027
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
Study: NCT01573975
Drug: 5RA-5RCM
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
Study: NCT01573975
Drug: 5RA-5RCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
Study: NCT02056340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04010669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hours infusion of 1000ml Normal Saline solution 0.9%
Study: NCT03446885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule administered orally
Study: NCT00690885
Drug: placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo lozenges
Study: NCT01648205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be given for first month.
Study: NCT02638727
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group treat with placebo dayley
Study: NCT01175941
Drug: NRL001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
Study: NCT01175941
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo - administered as a 2 g suppository, once daily for 7 days
Study: NCT03236974
Drug: AZD9496
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
Study: NCT00438113
Drug: Aggressive Blood Pressure control
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
Study: NCT00240162
Drug: PTK787/ZK 222584
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03314402
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00064844
Drug: Placebo gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
Study: NCT01355341
Drug: HERBMED PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Twice day for 6 month with lunch and dinner.
Study: NCT00296894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01010516
Drug: High-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 of rosuvastatin daily
Study: NCT00030511
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06311383
Drug: First-line chemtherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As of physicians choice
Study: NCT02978261
Drug: PLB1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
Study: NCT01507597
Drug: Native human Glucagon-like Peptide-1 ( GLP-1(7-36))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
Study: NCT01507597
Drug: Native human Glucagon-like Peptide-1 ( GLP-1(7-36))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
Study: NCT01507597
Drug: Native human Glucagon-like Peptide-1 ( GLP-1(7-36))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
Study: NCT03789318
Drug: CA-008 5 mg
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg CA-008 reconstituted in saline.
Study: NCT03789318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each cohort will use placebo reconstituted in saline.
Study: NCT03789318
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg IV administered intraoperatively
Study: NCT03789318
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg IV administered intraoperatively
Study: NCT03789318
Drug: CA-008 10 mg
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg CA-008 reconstituted in saline.
Study: NCT03789318
Drug: CA-008 15 mg
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg CA-008 reconstituted in saline.
Study: NCT00364637
Drug: Total intravenous anesthesia
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03276156
Drug: Apatinib plus S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
Study: NCT01386554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week).
Study: NCT00700661
Drug: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
Study: NCT03391050
Drug: APR-246
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT02951195
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet for oral administration.
Study: NCT02951195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-152.
Study: NCT02951195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-152/TEZ/IVA triple combination (TC).
Study: NCT02401139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01310855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00397696
Drug: [123I] 5-IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of \[123I\] 5-IA followed by SPECT imaging as described below. A second \[123I\] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123I\] 5IA imaging session.
Study: NCT00555893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
Study: NCT04138706
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.
Study: NCT00260026
Drug: Jin Fu Kang
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02232945
Drug: placebo of Banlangen(Radix Isatidis) granules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01026857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PLC colon release tablet 2 g/die for 4 weeks
Study: NCT01702415
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose, intravenous solution 5mg
Study: NCT01702415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00143273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg
Study: NCT01947738
Drug: VBY-891
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathepsin S inhibitor
Study: NCT01947738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02405793
Drug: Meloxicam Test Capsules
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02405793
Drug: Meloxicam Tablets
Normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00842712
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
Study: NCT00421863
Drug: Triatec HCT 5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT00421863
Drug: Lasix 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT00421863
Drug: Catapresan TTS 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT00421863
Drug: Pluscor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT02242344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183090
Drug: Meloxicam ampoule
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183090
Drug: Meloxicam tablet
Normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00715676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily
Study: NCT02927080
Drug: ACE-083 or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant fusion protein or normal saline.
Study: NCT04595591
Drug: 2mg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: titration dosing speeds of propofol at 2mg/kg/min
Study: NCT04595591
Drug: 1mg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: titration dosing speeds of propofol at 1mg/kg/min
Study: NCT04595591
Drug: 0.5mg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: titration dosing speeds of propofol at 0.5mg/kg/min
Study: NCT01377441
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
Study: NCT01377441
Drug: Placebo/Saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
Study: NCT00344513
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02177552
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04162327
Drug: IBI315
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.
Study: NCT04162327
Drug: IBI315
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
Study: NCT03958721
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/m2 twice daily taken by mouth every other week
Study: NCT03178864
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
Study: NCT04037605
Drug: Cosyntropin Injectable Product
Normalized name: cosyntropin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosyntropin injection is given twice per inpatient visit
Study: NCT04037605
Drug: Hydrocortisone Injection (also known as solu-cortef)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone IV push is given twice per inpatient visit
Study: NCT04037605
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Ketoconazole are given 4 times per inpatient visit
Study: NCT04037605
Drug: Saline solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Solution (placebo) for ganirelix subcutaneous injection
Study: NCT00216060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral placebo combined with androgen deprivation
Study: NCT00391534
Drug: modified release formulation of oxcarbazepine (OXC MR)
Normalized name: oxcarbazepine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
Study: NCT00391534
Drug: immediate release formulation of oxcarbazepine (OXC IR)
Normalized name: oxcarbazepine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
Study: NCT00003204
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00357539
Drug: Azithromycin (T1225)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03398681
Drug: Ferric carboymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]
Study: NCT02000973
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia combined with thoracic epidural 0.9% normal saline
Study: NCT03921086
Drug: Antihypertensive medication according to the study's algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm.
Study: NCT03138889
Drug: NKTR-214
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
Study: NCT03138889
Drug: NKTR-214
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
Study: NCT03138889
Drug: NKTR-214
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
Study: NCT01438957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02634684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study: NCT03924154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
Study: NCT03395886
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The noninvasive ventilation intolerated patients was sedated by remifentanil.
Study: NCT01053728
Drug: SAR161271
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study: NCT01514812
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral